Oncology News
- FDA Closes Out 2025 With 16 Oncology Approvals in Six WeeksThe US Food and Drug Administration (FDA) closed out 2025 with 16 hematology/oncology approvals in just six weeks, marking one of the most active periods of the year.… Read more: FDA Closes Out 2025 With 16 Oncology Approvals in Six Weeks
- Oral Menin-Based Triplet Shows Strong Early Activity in ND AMLThe phase II SAVE trial presented at the 2025 American Society of Hematology (ASH) Annual Meeting (Abstract 47) delivered early but compelling results from an all-oral regimen pairing… Read more: Oral Menin-Based Triplet Shows Strong Early Activity in ND AML
- FDA Approves Liso-Cel for R/R MZLOn December 4, 2025, the US Food and Drug Administration (FDA) approved the CD19/CD3-directed CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory marginal… Read more: FDA Approves Liso-Cel for R/R MZL